• Tue news: Pfizer explores sale of hospital drugs unit. FDA declines full approval of Ocaliva. AZ better than expected Q3 results. Pfizer, Lilly telehealth platforms draw scrutiny. 23andMe cutting lays off 40%. See more on our front page

Can Repatha and Migraine drug mitigate the sales of Neulasta, Epogen and Senipar generics?

Quote

anonymous

Guest
All those products will have competition entering this year or early 2019.

Migraine will have competition soon too so how feasible will it be to grow without significant price increases?
 




LAYOFFS LAYOFFS LAYOFFS!!!!!!!!!!! LAYOFFS LAYOFFS LAYOFFS!!!!!!!!!!! LAYOFFS LAYOFFS LAYOFFS!!!!!!!!!!! LAYOFFS LAYOFFS LAYOFFS!!!!!!!!!!! LAYOFFS LAYOFFS LAYOFFS!!!!!!!!!!! LAYOFFS LAYOFFS LAYOFFS!!!!!!!!!!! LAYOFFS LAYOFFS LAYOFFS!!!!!!!!!!! LAYOFFS LAYOFFS LAYOFFS!!!!!!!!!!! LAYOFFS LAYOFFS LAYOFFS!!!!!!!!!!! LAYOFFS LAYOFFS LAYOFFS!!!!!!!!!!! LAYOFFS LAYOFFS LAYOFFS!!!!!!!!!!! LAYOFFS LAYOFFS LAYOFFS!!!!!!!!!!! LAYOFFS LAYOFFS LAYOFFS!!!!!!!!!!! LAYOFFS LAYOFFS LAYOFFS!!!!!!!!!!! LAYOFFS LAYOFFS LAYOFFS!!!!!!!!!!!
 




Top Bottom
Back
Quote